id
stringlengths
9
11
source
stringclasses
1 value
title
stringlengths
15
560
text
stringlengths
2k
153k
PMC8249281
core_pubmed_pmc
Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine Abstract Combined antiretroviral treatments have significantly improved the morbidity and mortality related to HIV infection, thus transforming HIV infection into a chronic disease; however, the efficacy of antiretrovi...
PMC5703966
core_pubmed_pmc
Systemic clearance and brain distribution of carbazole-based cyanine compounds as Alzheimer’s disease drug candidates
Systemic clearance and brain distribution of carbazole-based cyanine compounds as Alzheimer’s disease drug candidates Abstract SLM and SLOH, two analogues of carbazole-based cyanine compounds, have been shown to inhibit β-amyloid peptide aggregation in vitro and in Alzheimer’s disease model mice, which could be potenti...
PMC11651071
core_pubmed_pmc
Development of the Curcumin Analog CA7 Liposome and Its Evaluation for Efficacy Against Cervical Cancer in vitro and in vivo
Development of the Curcumin Analog CA7 Liposome and Its Evaluation for Efficacy Against Cervical Cancer in vitro and in vivo Abstract Abstract Objective The objective of this study was to develop liposomes (LP) containing a curcumin (CU) analog CA7 to enhance its pharmacokinetic profile and anti-cervical cancer (CC) ef...
PMC9729727
core_pubmed_pmc
The effect of food on the pharmacokinetics of WXFL10203614, a potential selective JAK1 inhibitor, in healthy Chinese subjects
The effect of food on the pharmacokinetics of WXFL10203614, a potential selective JAK1 inhibitor, in healthy Chinese subjects Abstract Objective: This study was performed to investigate the effect of food on the pharmacokinetics (PK) of WXFL10203614 in healthy Chinese subjects. Methods: This was a randomized, open-labe...
PMC3586101
core_pubmed_pmc
Evaluation of the Pharmacokinetic Interaction between Lesogaberan (AZD3355) and Esomeprazole in Healthy Subjects
Evaluation of the Pharmacokinetic Interaction between Lesogaberan (AZD3355) and Esomeprazole in Healthy Subjects Abstract Background: Transient lower esophageal sphincter relaxations (TLESRs) have been identified as a primary cause of reflux events in patients with gastroesophageal reflux disease (GERD). GABAB receptor...
PMC8960439
core_pubmed_pmc
Transgenic Canola Oil Improved Blood Omega-3 Profiles: A Randomized, Placebo-Controlled Trial in Healthy Adults
Transgenic Canola Oil Improved Blood Omega-3 Profiles: A Randomized, Placebo-Controlled Trial in Healthy Adults Abstract Long-chain omega-3 polyunsaturated fatty acids (LC-ω3 PUFA), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), play key roles in physiological functions and disease prevention. Th...
PMC11579209
core_pubmed_pmc
Population pharmacokinetics and exposure–response relationships of maribavir in transplant recipients with cytomegalovirus infection
Population pharmacokinetics and exposure–response relationships of maribavir in transplant recipients with cytomegalovirus infection Abstract Maribavir is approved for management of post-transplant cytomegalovirus (CMV) infections refractory and/or resistant to CMV therapies at a dose of 400 mg twice daily (BID). Popul...
PMC6817767
core_pubmed_pmc
Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection Abstract Abstract There have been remarkable advances in drug development for the treatment of HIV-1 infection. From the co-formulation of combination antiretroviral therapy (cART) into single-tablet regimens to the development of long-acting ...
PMC6885506
core_pubmed_pmc
Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 ( SLCO1B1 ) Drug–Drug–Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole
Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 ( SLCO1B1 ) Drug–Drug–Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole Abstract Abstract Background Drug–drug interactions (DDIs) and drug–gene interactio...
PMC11649715
core_pubmed_pmc
Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis
Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis Abstract Abstract Background Omadacycline offers a potential advancement in the management of infections in people with cystic fibrosis (CF) because of its spectrum of activity, intrapulmonary penetration, and oral bioavailability. A prospective single-dos...
PMC11480974
core_pubmed_pmc
Development of CD33-Targeted Dual Drug-Loaded Nanoparticles for the Treatment of Pediatric Acute Myeloid Leukemia
Development of CD33-Targeted Dual Drug-Loaded Nanoparticles for the Treatment of Pediatric Acute Myeloid Leukemia Abstract Abstract Paediatric acute myeloid leukemia (AML) is a heterogeneous hematological malignancy still heavily reliant on traditional chemotherapeutic approaches. Combination treatments have shown to b...
PMC8843956
core_pubmed_pmc
Reversible Complete Heart Block in a Pregnant Woman Related to Sertraline Treatment
Reversible Complete Heart Block in a Pregnant Woman Related to Sertraline Treatment Abstract Complete heart block (CHB) is a serious condition, usually affecting older patients. We report a case of CHB in a 31-year-old pregnant woman treated with sertraline in whom atrioventricular (AV) conduction normalized after disc...
PMC12802081
core_pubmed_pmc
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral TYK2 Inhibitor D‐2570 in Healthy Subjects: A First‐in‐Human Phase I Study
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral TYK2 Inhibitor D‐2570 in Healthy Subjects: A First‐in‐Human Phase I Study Abstract ABSTRACT D‐2570 selectively binds to the pseudokinase domain of tyrosine kinase 2, which mediates the downstream cytokine signaling pathways involved in immune regu...
PMC9487926
core_pubmed_pmc
Transdermal delivery of colchicine using dissolvable microneedle arrays for the treatment of acute gout in a rat model
Transdermal delivery of colchicine using dissolvable microneedle arrays for the treatment of acute gout in a rat model Abstract Abstract Colchicine (Col) is used to prevent and treat acute gout flare; however, its therapeutic use is strictly limited owing to severe gastrointestinal side effects after oral administratio...
PMC11156749
core_pubmed_pmc
Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: implications for therapeutic response and monitoring
Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: implications for therapeutic response and monitoring Abstract Background Imatinib treatment for certain cancers can lead to elevated creatine kinase (CK) levels, potentially indicating muscle injury, and ongoing research aims to ...
PMC12743464
core_pubmed_pmc
Engineering Optimized Nanostructured Lipid Carriers for Astaxanthin: A Response Surface Methodology Approach
Engineering Optimized Nanostructured Lipid Carriers for Astaxanthin: A Response Surface Methodology Approach Abstract Abstract Introduction The xanthophyll carotenoid astaxanthin is well-known for its potent antioxidant properties, which are superior to those of other antioxidants such as vitamins C and E. However, thi...
PMC6221039
core_pubmed_pmc
Amenamevir: Studies of Potential CYP2C8‐ and CYP2B6‐Mediated Pharmacokinetic Interactions With Montelukast and Bupropion in Healthy Volunteers
Amenamevir: Studies of Potential CYP2C8‐ and CYP2B6‐Mediated Pharmacokinetic Interactions With Montelukast and Bupropion in Healthy Volunteers Abstract Abstract Amenamevir (formerly ASP2151) induces cytochrome P450 (CYP)2B6 and CYP3A4 and inhibits CYP2C8. We conducted 2 studies, 1 using montelukast as a probe to assess...
PMC4223074
core_pubmed_pmc
Rapid and Simultaneous Quantification of Levetiracetam and Its Carboxylic Metabolite in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry
Rapid and Simultaneous Quantification of Levetiracetam and Its Carboxylic Metabolite in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry Abstract A simple liquid chromatography tandem mass spectrometry method was developed and validated according to the guidelines of the US Food and Drug Administration an...
PMC7335633
core_pubmed_pmc
Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches
Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches Abstract WHO has declared the outbreak of COVID-19 as a public health emergency of international concern. The ever...
PMC9543705
core_pubmed_pmc
Profiling of warfarin pharmacokinetics‐associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics‐dosing algorithm
Profiling of warfarin pharmacokinetics‐associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics‐dosing algorithm Abstract Abstract Background Warfarin dose variability observed in patients is attributed to variation in genes involved in the w...
PMC10520102
core_pubmed_pmc
Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies Abstract Background and Objective Mirikizumab is a humanized anti-interleukin-23-p19 monoclonal antibody being developed for ulcerative colitis and Crohn’s disease. This analysis charact...
PMC5007276
core_pubmed_pmc
Pharmacokinetics and excretion of 14 C-omacetaxine in patients with advanced solid tumors
Pharmacokinetics and excretion of 14 C-omacetaxine in patients with advanced solid tumors Abstract Summary Background Omacetaxine mepesuccinate is indicated in adults with chronic myeloid leukemia resistant and/or intolerant to ≥ 2 tyrosine kinase inhibitor treatments. This phase I study assessed the disposition, elimi...
PMC8301577
core_pubmed_pmc
Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers
Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers Abstract Abstract Trandolapril, an angiotensin‐converting enzyme inhibitor prodrug, needs to be activated by carboxylesterase 1 (CES1) in the liver to exert its...
PMC6744479
core_pubmed_pmc
Mimicking in-vivo exposures to drug combinations in-vitro : anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection
Mimicking in-vivo exposures to drug combinations in-vitro : anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection Abstract Here, we evaluate protocol requirements to mimic therapeutically relevant drug concentrations at the site of infection (i.e. lung lesion) in an in-vitro hollow fibre model...
PMC10746753
core_pubmed_pmc
Preclinical Pharmacokinetics and Translational Pharmacokinetic/Pharmacodynamic Modeling of M8891, a Potent and Reversible Inhibitor of Methionine Aminopeptidase 2
Preclinical Pharmacokinetics and Translational Pharmacokinetic/Pharmacodynamic Modeling of M8891, a Potent and Reversible Inhibitor of Methionine Aminopeptidase 2 Abstract Abstract Introduction M8891 is a selective and reversible inhibitor of methionine aminopeptidase 2 (MetAP2). We describe translational research to d...
PMC8853508
core_pubmed_pmc
Evidence for the early emergence of piperaquine-resistant Plasmodium falciparum malaria and modeling strategies to mitigate resistance
Evidence for the early emergence of piperaquine-resistant Plasmodium falciparum malaria and modeling strategies to mitigate resistance Abstract Abstract Multidrug-resistant Plasmodium falciparum parasites have emerged in Cambodia and neighboring countries in Southeast Asia, compromising the efficacy of first-line antim...
PMC5108032
core_pubmed_pmc
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy Abstract The antiplasmodial activity, DMPK properties, and efficacy of a series of quinoline-4-carboxamides are described. This series was identified from a phenotypic screen...
PMC11724043
core_pubmed_pmc
Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial
Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial Abstract We conducted a phase I trial to determine the optimal dose of triplet therapy with the tyrosine kinase inhibitor sitravatinib plus nivolumab plus ipilimumab in 22 previously unt...
PMC11526151
core_pubmed_pmc
In silico prediction of some pharmacokinetic, safety, biological activity and molecular docking studies of 1-piperazine indole hybrid with nicotinic amide and nicotinic acid and their analogues
In silico prediction of some pharmacokinetic, safety, biological activity and molecular docking studies of 1-piperazine indole hybrid with nicotinic amide and nicotinic acid and their analogues Abstract Abstract Background: In silico predictions are now being utilized in drug discovery and design to assess the physicoc...
PMC7808403
core_pubmed_pmc
Recent Advancement in Nanotechnology-Based Drug Delivery System Against Viral Infections
Recent Advancement in Nanotechnology-Based Drug Delivery System Against Viral Infections Abstract Abstract In the last few decades, the exponential rise in the incidence of viral infections sets a global health emergency across the world. The biomimetic architecture, the ability to hijack host immune responses, continu...
PMC3990384
core_pubmed_pmc
Pharmacokinetics of Zidovudine Dosed Twice Daily According to World Health Organization Weight Bands in Ugandan HIV-infected Children
Pharmacokinetics of Zidovudine Dosed Twice Daily According to World Health Organization Weight Bands in Ugandan HIV-infected Children Abstract Supplemental Digital Content is available in the text. Keywords: zidovudine, pharmacokinetics, HIV, children, Africa Abstract Data on zidovudine pharmacokinetics in children dos...
PMC6594244
core_pubmed_pmc
Effects of Oral Ginger Supplementation on the INR
Effects of Oral Ginger Supplementation on the INR Abstract Abstract Although there are competing options for anticoagulation, many Americans remain on warfarin. Concurrently, the use of alternative medicines is on the rise. With that, the potential for interactions between them is increasing. Ginger has gained populari...
PMC8748612
core_pubmed_pmc
Maximizing response to intratumoral immunotherapy in mice by tuning local retention
Maximizing response to intratumoral immunotherapy in mice by tuning local retention Abstract Abstract Direct injection of therapies into tumors has emerged as an administration route capable of achieving high local drug exposure and strong anti-tumor response. A diverse array of immune agonists ranging in size and targ...
PMC9323134
core_pubmed_pmc
Monocrotaline Toxicity Alters the Function of Hepatocyte Membrane Transporters in Rats
Monocrotaline Toxicity Alters the Function of Hepatocyte Membrane Transporters in Rats Abstract Pyrrolizidine alkaloid monocrotaline (MCT) induces sinusoidal obstruction syndrome (SOS) in rats characterised by a sinusoidal congestive obstruction. Additionally, MCT administration decreases the biliary excretion of gadob...
PMC6691366
core_pubmed_pmc
Single-dose pharmacokinetics of meropenem in porcine cancellous bone determined by microdialysis
Single-dose pharmacokinetics of meropenem in porcine cancellous bone determined by microdialysis Abstract Objectives Meropenem may be an important drug in the treatment of open tibial fractures and chronic osteomyelitis. Therefore, the objective of this study was to describe meropenem pharmacokinetics in plasma, subcut...
PMC10394562
core_pubmed_pmc
Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa Abstract Background Efanesoctocog alfa is a new class of factor (F) VIII replacement therapy designed to provide high sustained factor levels f...
PMC6986439
core_pubmed_pmc
Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers
Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers Abstract Abstract A pilot study was conducted aiming at specifying sultiame's pharmacokinetic profile, completed by in vitro assays evaluating the intraerythrocytic transfer of sultiame and by a phar...
PMC8901605
core_pubmed_pmc
Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia Abstract B-cell receptor (BCR) signaling pathway and Bcl-2 family prosurvival proteins, specifically Bcl-2 and Mcl-1, are functional in the pathobiology of chronic lymphocytic leukemia (CLL). A pivotal and apical molecule...
PMC4614199
core_pubmed_pmc
Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors Abstract Abstract Purpose OPB-31121 is an oral STAT3 inhibitor with a good preclinical antitumor activity. This phase I dose-escalation study of OPB-31121 was conducted to determine maximum-tolerated dose (MTD), safety, pharmaco...
PMC11773116
core_pubmed_pmc
Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer
Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer Abstract Abstract Aims Sunitinib exhibits considerable interindividual variability in exposure. While the target total plasma concentration of sunitinib and its active metabolite is 50–87.5 ng/mL for the intermittent dosin...
PMC7000638
core_pubmed_pmc
Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study
Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study Abstract Background/Aims PF-00547659 is a monoclonal antibody against human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) that prevents the binding of α4β7 + lymphocytes to MAdCAM-expressi...
PMC8010309
core_pubmed_pmc
Application of a Physiologically Based Pharmacokinetic Model to Characterize Time-dependent Metabolism of Voriconazole in Children and Support Dose Optimization
Application of a Physiologically Based Pharmacokinetic Model to Characterize Time-dependent Metabolism of Voriconazole in Children and Support Dose Optimization Abstract Background: Voriconazole is a potent antifungal drug with complex pharmacokinetics caused by time-dependent inhibition and polymorphisms of metabolizi...
PMC9476775
core_pubmed_pmc
Brusatol: A potential anti-tumor quassinoid from Brucea javanica
Brusatol: A potential anti-tumor quassinoid from Brucea javanica Abstract Brusatol, a triterpene lactone compound mainly from Brucea javanica , sensitizes a broad spectrum of cancer cells. It is known as a specific inhibitor of nuclear factor-erythroid 2-related factor 2 (Nrf2) pathway. In this review, we provide a com...
PMC8741190
core_pubmed_pmc
Real-time monitoring of drug pharmacokinetics within tumor tissue in live animals
Real-time monitoring of drug pharmacokinetics within tumor tissue in live animals Abstract Abstract The efficacy and safety of a chemotherapy regimen fundamentally depends on its pharmacokinetics. This is currently measured based on blood samples, but the abnormal vasculature and physiological heterogeneity of the tumo...
PMC7881784
core_pubmed_pmc
Improved Pharmacodynamic Potential of Rosuvastatin by Self-Nanoemulsifying Drug Delivery System: An in vitro and in vivo Evaluation
Improved Pharmacodynamic Potential of Rosuvastatin by Self-Nanoemulsifying Drug Delivery System: An in vitro and in vivo Evaluation Abstract Purpose The purpose of this proposed research was to investigate a nano-formulation developed using self-nanoemulsifying drug delivery system (SNEDDS) to improve the pharmacodynam...
PMC5236087
core_pubmed_pmc
A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations
A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations Abstract Purpose Predicting target site drug concentration in the brain is of key importance for the successful development of drugs acting on the central nervous system. We propose a g...
PMC8420880
core_pubmed_pmc
Comparison of Drug Availability in the Inner Ear After Oral, Transtympanic, and Combined Administration
Comparison of Drug Availability in the Inner Ear After Oral, Transtympanic, and Combined Administration Abstract Abstract Although combination of oral and transtympanic drug therapy (CT) has been proved more effective and safer for idiopathic sudden sensorineural hearing loss (ISSNHL) by some clinical trials, there are...
PMC10582678
core_pubmed_pmc
A randomized, controlled single, and multiple ascending dose trial of the safety, pharmacokinetics and pharmacodynamics of SN1011 in healthy subjects
A randomized, controlled single, and multiple ascending dose trial of the safety, pharmacokinetics and pharmacodynamics of SN1011 in healthy subjects Abstract Abstract The purpose of this study was to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SN1011, a novel Bruton tyrosine kinase ...
PMC10196163
core_pubmed_pmc
The pharmacokinetics and pharmacodynamics of esomeprazole in sheep after intravenous dosing
The pharmacokinetics and pharmacodynamics of esomeprazole in sheep after intravenous dosing Abstract Abomasal (gastric) ulceration is a morbidity in sheep, and currently, there is a paucity of pharmacokinetic and pharmacodynamic data for gastroprotectant drugs reported for this species. The proton pump inhibitor esomep...
PMC8577762
core_pubmed_pmc
Effects of concurrent and staggered dosing of semi-solid enteral nutrients on pharmacokinetic behavior of antiepileptic drugs after oral administration in rats
Effects of concurrent and staggered dosing of semi-solid enteral nutrients on pharmacokinetic behavior of antiepileptic drugs after oral administration in rats Abstract Abstract Background The use of enteral nutrients plays a highly important role in accurate nutrition management, but limited information is currently a...
PMC12163612
core_pubmed_pmc
Gender-stratified 9-month comparison of paliperidone extended-release tablets and paliperidone palmitate injection in schizophrenia
Gender-stratified 9-month comparison of paliperidone extended-release tablets and paliperidone palmitate injection in schizophrenia Abstract Abstract Background Gender differences in antipsychotic efficacy for schizophrenia (SCZ) remain understudied despite evidence of sex-dependent pharmacokinetic, neurobiological, an...
PMC11651182
core_pubmed_pmc
Identification of fibrinogen as a plasma protein binding partner for lecanemab biosimilar IgG
Identification of fibrinogen as a plasma protein binding partner for lecanemab biosimilar IgG Abstract Abstract Objective Recombinant monoclonal therapeutic antibodies like lecanemab, which target amyloid beta in Alzheimer's disease, offer a promising approach for modifying the disease progression. Due to its relativel...
PMC6168621
core_pubmed_pmc
Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Δ 9 -THC
Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Δ 9 -THC Abstract Abstract Recreational use of marijuana is associated with few adverse effects, but abuse of synthetic cannabinoids (SCBs) can result...
PMC11675703
core_pubmed_pmc
Injectable and In Situ Phospholipid-Based Phase Separation Gel for Sustained Delivery of Altrenogest
Injectable and In Situ Phospholipid-Based Phase Separation Gel for Sustained Delivery of Altrenogest Abstract Altrenogest is a key regulatory hormone for intensive and batch management of reserve sows in breeding farms. As a synthetic hormone, altrenogest could make ovaries stay at the initial stage of follicles and in...
PMC9292509
core_pubmed_pmc
A Dose‐Confirmation Phase 1 Study to Evaluate the Safety and Pharmacology of Glucarpidase in Healthy Volunteers
A Dose‐Confirmation Phase 1 Study to Evaluate the Safety and Pharmacology of Glucarpidase in Healthy Volunteers Abstract Abstract Glucarpidase rapidly decomposes methotrexate. A phase 1 study of glucarpidase in an open‐label, randomized parallel group was conducted to evaluate the safety, pharmacokinetics, and other ph...
PMC7559746
core_pubmed_pmc
Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib
Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib Abstract Prior studies have demonstrated an organic anion transporter 6 (OAT6)-mediated accumulation of sorafenib in keratinocytes. The OAT6 inhibitor probenecid decreases sorafenib uptake in skin and might, therefore, decrease sorafenib-...
PMC7032114
core_pubmed_pmc
Pharmacokinetics of a ternary conjugate based pH-responsive 10-HCPT prodrug nano-micelle delivery system
Pharmacokinetics of a ternary conjugate based pH-responsive 10-HCPT prodrug nano-micelle delivery system Abstract Abstract A pH-responsive conjugate based 10-hydroxycamptothecin-thiosemicarbazide-polyethene glycol 2000 (10-HCPT-hydro-PEG) nano-micelles were prepared in our previous study. In the present study, ultra-pe...
PMC6226112
core_pubmed_pmc
No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy
No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy Abstract Abstract The aims of these phase I trials were to evaluate the pharmacokinetic interaction between elbasvir (EBR) or grazoprevir (GZR) and ...
PMC6401406
core_pubmed_pmc
Quantitative MALDI Imaging of Spatial Distributions and Dynamic Changes of Tetrandrine in Multiple Organs of Rats
Quantitative MALDI Imaging of Spatial Distributions and Dynamic Changes of Tetrandrine in Multiple Organs of Rats Abstract Detailed spatio-temporal information on drug distribution in organs is of paramount importance to assess drug clinically-relevant properties and potential side-effects. Matrix-assisted laser desorp...
PMC10733202
core_pubmed_pmc
Active Uptake of Oxycodone at Both the Blood-Cerebrospinal Fluid Barrier and The Blood-Brain Barrier without Sex Differences: A Rat Microdialysis Study
Active Uptake of Oxycodone at Both the Blood-Cerebrospinal Fluid Barrier and The Blood-Brain Barrier without Sex Differences: A Rat Microdialysis Study Abstract Background Oxycodone active uptake across the blood-brain barrier (BBB) is associated with the putative proton-coupled organic cation (H + /OC) antiporter syst...
PMC7015960
core_pubmed_pmc
Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects
Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects Abstract Purpose Zanubrutinib (BGB-3111) is a potent Bruton’s tyrosine kinase inhibitor with promising clinical activity in B-cell malignancies. Zanubrutinib was sho...
PMC5909787
core_pubmed_pmc
Population pharmacokinetics and dosing optimization of cefathiamidine in children with hematologic infection
Population pharmacokinetics and dosing optimization of cefathiamidine in children with hematologic infection Abstract Abstract Purpose Cefathiamidine, a first-generation cephalosporin, has approval from the China Food and Drug Administration for the treatment of infections caused by susceptible bacteria in both adults ...
PMC10725258
core_pubmed_pmc
A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV prevention
A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV prevention Abstract Abstract A priori use of mathematical modeling and simulation to predict outcomes from incomplete adherence or reduced frequency dosing strategies may mitigate the risk of clinical tri...
PMC10462944
core_pubmed_pmc
Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial
Extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV-negative women: study protocol for the randomised, placebo-controlled double-blinded, phase 2 CAPRISA 012C trial Abstract Abstract Introduction Women-controlled HIV prevention technologies that overcome adherence challenges of available ...
PMC8880204
core_pubmed_pmc
Application of Semi-Mechanistic Pharmacokinetic and Pharmacodynamic Model in Antimicrobial Resistance
Application of Semi-Mechanistic Pharmacokinetic and Pharmacodynamic Model in Antimicrobial Resistance Abstract Antimicrobial resistance is a major public health issue. The pharmacokinetic/pharmacodynamic (PK/PD) model is an essential tool to optimize dosage regimens and alleviate the emergence of resistance. The semi-m...
PMC12562389
core_pubmed_pmc
In Silico Network Pharmacology, Molecular Docking, and Molecular Dynamics Analysis of Rosemary-Derived Compounds as Potential HSP90 Inhibitors for Cancer Therapy
In Silico Network Pharmacology, Molecular Docking, and Molecular Dynamics Analysis of Rosemary-Derived Compounds as Potential HSP90 Inhibitors for Cancer Therapy Abstract Abstract Cancer remains a major global health challenge, emphasizing the need for new and effective therapies. This study investigates the anticancer...
PMC12569548
core_pubmed_pmc
Recurrent fexuprazan‐induced liver injury following unintentional re‐exposure
Recurrent fexuprazan‐induced liver injury following unintentional re‐exposure Abstract Fexuprazan, a potassium‐competitive acid blocker, is increasingly used for the treatment of gastroesophageal reflux disease in South Korea. While generally well tolerated, data regarding its hepatotoxic potential are scarce. We repor...
PMC8399031
core_pubmed_pmc
Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study
Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study Abstract Factors associated with olaparib toxicity remain unknown in ovarian cancer patients. The large inter-individual variability in olaparib pharmacokinetics could contrib...
PMC11770187
core_pubmed_pmc
Unveiling the biological activities of Heliotropium indicum L. plant extracts: anti-inflammatory activities, GC–MS analysis, and in-silico molecular docking
Unveiling the biological activities of Heliotropium indicum L. plant extracts: anti-inflammatory activities, GC–MS analysis, and in-silico molecular docking Abstract Heliotropium indicum is well-known for its diverse medicinal properties, traditionally utilized to treat ailments such as diabetes, obesity, bacterial inf...
PMC11939361
core_pubmed_pmc
diAcCA, a Pro-Drug for Carnosic Acid That Activates the Nrf2 Transcriptional Pathway, Shows Efficacy in the 5xFAD Transgenic Mouse Model of Alzheimer’s Disease
diAcCA, a Pro-Drug for Carnosic Acid That Activates the Nrf2 Transcriptional Pathway, Shows Efficacy in the 5xFAD Transgenic Mouse Model of Alzheimer’s Disease Abstract The antioxidant/anti-inflammatory compound carnosic acid (CA) is a phenolic diterpene found in the herbs rosemary and sage. Upon activation, CA manifes...
PMC10085060
core_pubmed_pmc
A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850
A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850 Abstract Abstract Background: Overexpression of metabotropic glutamate receptor 1 (GRM1) has been implicated in the pathogenesis of multiple cancers. Riluzole, an inhibitor of glutamate release, showed synergistic antitumor act...
PMC8522776
core_pubmed_pmc
Determinants of primaquine and carboxyprimaquine exposures in children and adults with Plasmodium vivax malaria
Determinants of primaquine and carboxyprimaquine exposures in children and adults with Plasmodium vivax malaria Abstract Abstract Background Primaquine is the only widely available drug for radical cure of Plasmodium vivax malaria. There is uncertainty whether the pharmacokinetic properties of primaquine are altered si...
PMC5715499
core_pubmed_pmc
Paracetamol clinical dosing routine leads to paracetamol underexposure in an adult severely ill sub-Saharan African hospital population: a drug concentration measurement study
Paracetamol clinical dosing routine leads to paracetamol underexposure in an adult severely ill sub-Saharan African hospital population: a drug concentration measurement study Abstract Background Hospitals in sub-Saharan Africa (SSA) continue to receive high numbers of severely ill (HIV-infected) patients with physical...
PMC12804367
core_pubmed_pmc
A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutations
A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutations Abstract Abstract Background Protein kinase B (AKT)-directed therapies offer promise for patients with cancers harboring germline and somatic phosphatase and tensin homolog ( PTEN ) mutations. TAS-117 is an ...
PMC12285691
core_pubmed_pmc
Allopregnanolone Concentrations After Ascending Single Dose Administration of Progesterone to Healthy Volunteers
Allopregnanolone Concentrations After Ascending Single Dose Administration of Progesterone to Healthy Volunteers Abstract ABSTRACT Background Postpartum depression (PPD) is associated with significant morbidity and mortality. It affects as many as 11.5% of women giving birth. Allopregnanolone (an endogenous progesteron...
PMC12642065
core_pubmed_pmc
Cohort profile: the pharmacogenomics and pharmacokinetics study in Ghanaian HIV patients (GenoPharm-GH)
Cohort profile: the pharmacogenomics and pharmacokinetics study in Ghanaian HIV patients (GenoPharm-GH) Abstract Abstract Background The GenoPharm-GH project initiated in 2019, as a longitudinal, multi-site observational cohort study aimed at bridging gaps in understanding the influence of host genetics, pharmacokineti...
PMC9440868
core_pubmed_pmc
Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose–response model
Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose–response model Abstract Abstract Aims Many patients are unable to achieve guideline-recommended LDL cholesterol (LDL-C) targets, despite taking maximally tolerated lipid-lowering therapy. Bempedoic acid, a competitive inhibitor of...
PMC12746359
core_pubmed_pmc
Feasibility of dried blood spot collection for caffeine pharmacokinetic studies in microgravity: Insights from parabolic flight campaigns
Feasibility of dried blood spot collection for caffeine pharmacokinetic studies in microgravity: Insights from parabolic flight campaigns Abstract Abstract Aims Therapeutic drug monitoring for astronauts faces limitations in conventional blood sampling and sample management onboard the international space station. Here...
PMC9145325
core_pubmed_pmc
Self-Nanoemulsifying Drug Delivery System (SNEDDS) of Apremilast: In Vitro Evaluation and Pharmacokinetics Studies
Self-Nanoemulsifying Drug Delivery System (SNEDDS) of Apremilast: In Vitro Evaluation and Pharmacokinetics Studies Abstract Psoriatic arthritis is an autoimmune disease of the joints that can lead to persistent inflammation, irreversible joint damage and disability. The current treatments are of limited efficacy and in...
PMC8080052
core_pubmed_pmc
Antidepressant activity of rose oxide essential oil: possible involvement of serotonergic transmission
Antidepressant activity of rose oxide essential oil: possible involvement of serotonergic transmission Abstract Abstract Rose oxide (RO) is a monoterpene found in rose oil fragrances. This monoterpene has been reported to possess anti-inflammatory activity, however, little is known regarding its pharmacological activit...
PMC7497674
core_pubmed_pmc
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma Abstract Summary Purpose Galunisertib, a TGF-β inhibitor, has demonstrated antitumor effects in...
PMC9534738
core_pubmed_pmc
Physiologically Based Pharmacokinetic (PBPK) Model-Informed Dosing Guidelines for Pediatric Clinical Care: A Pragmatic Approach for a Special Population
Physiologically Based Pharmacokinetic (PBPK) Model-Informed Dosing Guidelines for Pediatric Clinical Care: A Pragmatic Approach for a Special Population Abstract Physiologically based pharmacokinetic (PBPK) modeling can be an attractive tool to increase the evidence base of pediatric drug dosing recommendations by maki...
PMC6985102
core_pubmed_pmc
A general covalent binding model between cytotoxic selenocompounds and albumin revealed by mass spectrometry and X-ray absorption spectroscopy
A general covalent binding model between cytotoxic selenocompounds and albumin revealed by mass spectrometry and X-ray absorption spectroscopy Abstract Selenocompounds (SeCs) are promising therapeutic agents for a wide range of diseases including cancer. The treatment results are heterogeneous and dependent on both the...
PMC6497007
core_pubmed_pmc
Development, Validation of LC-MS/MS Method and Determination of Pharmacokinetic Parameters of the Stroke Neuroprotectant Neurounina-1 in Beagle Dog Plasma After Intravenous Administration
Development, Validation of LC-MS/MS Method and Determination of Pharmacokinetic Parameters of the Stroke Neuroprotectant Neurounina-1 in Beagle Dog Plasma After Intravenous Administration Abstract Neurounina-1 [chemical name: 7-nitro-5-phenyl-1-(pyrrolidin-1-ylmethyl)-1H-benzo[e]diazepin-2(3H)-one] is a new compound pr...
PMC5113768
core_pubmed_pmc
Extended‐Release Once‐Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate‐Release Tofacitinib and Impact of Food
Extended‐Release Once‐Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate‐Release Tofacitinib and Impact of Food Abstract Abstract Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. An extended‐release (XR) formulation has been designed to provi...
PMC12402090
core_pubmed_pmc
Pharmacokinetic and pharmacodynamic studies of injectable nocathiacin as a novel antibacterial agent
Pharmacokinetic and pharmacodynamic studies of injectable nocathiacin as a novel antibacterial agent Abstract The extreme hydrophobicity of nocathiacin, a potent thiopeptide antibiotic against multidrug-resistant (MDR) Gram-positive pathogens, has limited its clinical development. This study formulated an injectable ly...
PMC5028085
core_pubmed_pmc
Application of physiologically based pharmacokinetic modeling in predicting drug–drug interactions for sarpogrelate hydrochloride in humans
Application of physiologically based pharmacokinetic modeling in predicting drug–drug interactions for sarpogrelate hydrochloride in humans Abstract Background Evaluating the potential risk of metabolic drug–drug interactions (DDIs) is clinically important. Objective To develop a physiologically based pharmacokinetic (...
PMC10896214
core_pubmed_pmc
Somatostatin Receptor Subtype-2 Targeting System for Specific Delivery of Temozolomide
Somatostatin Receptor Subtype-2 Targeting System for Specific Delivery of Temozolomide Abstract Temozolomide (TMZ) is a DNA alkylating agent that produces objective responses in patients with neuroendocrine tumors (NETs) when the DNA repair enzyme O 6 -methylguanine-DNA methyltransferase (MGMT) is inactivated. At high ...
PMC9199870
core_pubmed_pmc
Pharmacokinetics/pharmacodynamics of L‐ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes
Pharmacokinetics/pharmacodynamics of L‐ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes Abstract Abstract Hepatic encephalopathy (HE) is a serious neurocognitive complication of liver dysfunction, often associated with elevated plasma ...
PMC12065821
core_pubmed_pmc
The pharmacokinetic-nephrotoxicity relationships of CMS and CMS-E2 from the perspective of plasma and kidney drug concentrations in rats
The pharmacokinetic-nephrotoxicity relationships of CMS and CMS-E2 from the perspective of plasma and kidney drug concentrations in rats Abstract Abstract Nephrotoxicity has seriously affected the clinical application of colistin methanesulphonate (CMS). Colistin B methanesulphonate (CMS-E2) is a novel polymyxin develo...
PMC12516152
core_pubmed_pmc
Physiologically Based Pharmacokinetic Modeling of Valemetostat to Inform Dose Recommendations When Coadministered With CYP3A /P‐gp Modulators
Physiologically Based Pharmacokinetic Modeling of Valemetostat to Inform Dose Recommendations When Coadministered With CYP3A /P‐gp Modulators Abstract ABSTRACT Valemetostat tosylate (valemetostat) is an oral, potent, selective dual inhibitor of enhancer of zeste homolog (EZH)2 and EZH1, approved in Japan for the treatm...
PMC8717895
core_pubmed_pmc
Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG
Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG Abstract Abstract Background Platelet-derived growth factor receptor (PDGFR) signaling has been directly implicated in pediatric high-grade gliomagenesis. This stud...
PMC7406372
core_pubmed_pmc
Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not
Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not Abstract Introduction Body weight can affect exposure, safety and efficacy of antibody-based therapies; sometimes these effects may not be clinically relevant. Panitumumab is approved for wild-type RAS metastatic colorectal can...
PMC12015958
core_pubmed_pmc
Predicting Liver-Related In Vitro Endpoints with Machine Learning to Support Early Detection of Drug-Induced Liver Injury
Predicting Liver-Related In Vitro Endpoints with Machine Learning to Support Early Detection of Drug-Induced Liver Injury Abstract Abstract Drug-induced liver injury (DILI) is a major cause of drug development failures and postmarket drug withdrawals, posing significant challenges to public health and pharmaceutical re...
PMC3293351
core_pubmed_pmc
Pharmacokinetics and Excretion Studies on CDRI-85/92, an Antiulcer Proton Pump Inhibitor
Pharmacokinetics and Excretion Studies on CDRI-85/92, an Antiulcer Proton Pump Inhibitor Abstract Abstract CDRI 85/92 is an antiulcer pharmacophore and a proton pump inhibitor, which is in an advanced stage of preclinical trials. In view of its importance, pharmacokinetic and excretion were studied in Sprague Dawley ra...
PMC10144034
core_pubmed_pmc
Senkyunolide I: A Review of Its Phytochemistry, Pharmacology, Pharmacokinetics, and Drug-Likeness
Senkyunolide I: A Review of Its Phytochemistry, Pharmacology, Pharmacokinetics, and Drug-Likeness Abstract Abstract Senkyunolide I (SI) is a natural phthalide that has drawn increasing interest for its potential as a cardio-cerebral vascular drug candidate. In this paper, the botanical sources, phytochemical characteri...
PMC6302520
core_pubmed_pmc
Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study
Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study Abstract Abstract Background Venous thromboembolism (VTE) is a relatively rare condition in childhood with treatment mainly based on extrapolation from studies in adults. Therefore, clini...
PMC7818492
core_pubmed_pmc
Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese Subjects
Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese Subjects Abstract Abstract This phase 1, open‐label, single‐center study evaluated the pharmacokinetics (PK), pharmacodynamics, safety, and tolerability of single‐dose emicizumab in healthy Chinese males. ...
PMC6220931
core_pubmed_pmc
Interchangeability of Generic Drugs: A Nonparametric Pharmacokinetic Model of Gabapentin Generic Drugs
Interchangeability of Generic Drugs: A Nonparametric Pharmacokinetic Model of Gabapentin Generic Drugs Abstract Substitution by generic drugs is allowed when bioequivalence to the originator drug has been established. However, it is known that similarity in exposure may not be achieved at every occasion for all individ...
PMC12677105
core_pubmed_pmc
Pharmacodynamics, Safety, and Tolerability of Pyridostigmine Bromide in Heart Failure
Pharmacodynamics, Safety, and Tolerability of Pyridostigmine Bromide in Heart Failure Abstract Abstract Background Pyridostigmine bromide is a short-acting carbamate acetylcholinesterase inhibitor that has been shown to acutely augment parasympathetic signaling in cardiovascular disease populations. Objective This stud...